TY - GEN AU - Gilles Salles AU - Martin Barrett AU - Robin Foà AU - Joerg Maurer AU - Susan O'Brien AU - Nancy Valente AU - Michael Wenger AU - David G Maloney TI - Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. PY - 2017/// CY - [Place of publication not identified] PB - [publisher not identified] KW - Safety KW - Monoclonal antibody KW - CD20 KW - Treatment outcome KW - Follicular Lymphoma KW - Rituximab KW - B. Sc. Medical Laboratory Science KW - UMUN open access collection KW - hematology KW - Review articles N1 - Publication type: Review article; Linked open-access copy: published version; Open access; no subscription required for the linked open-access version N2 - Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. Funding F. Hoffmann-La Roche Ltd., Basel, Switzerland UR - https://europepmc.org/articles/PMC5656728 ER -